SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 20, 2019
|(Exact name of registrant as specified in its charter)|
|(State or other jurisdiction of incorporation)|
|(Commission File Number)||(I.R.S. Employer Identification Number)|
|2850 Frontier Drive|
|(Address of principal executive offices)||(Zip Code)|
Registrant’s telephone number, including area code: (574) 268-6379
|(Former name or former address, if changed since last report)|
Securities registered pursuant to Section 12(b) of the Act:
|Title of Each Class||Trading Symbol(s)||Name of each exchange on which registered|
|Common Stock, $0.00025 par value per share||KIDS||The NASDAQ Stock Market LLC|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|[ ]||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|[ ]||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|[ ]||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act (17 CFR 230.405) or Rule 12b-2 under the Exchange Act (17 CFR 240.12b-2).
Emerging growth company [X]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act [X]
Item 7.01. Regulation FD Disclosure.
On December 20, 2019, OrthoPediatrics Corp. (“the Company”) issued a press release announcing the domestic launch of its 33rd surgical system, QuickPackTM, a fully synthetic bone graft substitute featuring a high viscosity, calcium phosphate cement that closely mimics the mineral phase of natural bone. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.
The Company does not intend for this Item 7.01 or Exhibit 99.1 to be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
* * * * * *
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: December 20, 2019||By:||/s/ Daniel J. Gerritzen|
|Daniel J. Gerritzen, |
General Counsel and Secretary
OrthoPediatrics Corp. Announces U.S. Launch of QuickPack™
WARSAW, Indiana, December 20, 2019 — OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, is pleased to announce the U.S. launch of QuickPack™, a fully synthetic bone graft substitute featuring a high viscosity, calcium phosphate cement that closely mimics the mineral phase of natural bone.
With mechanical properties close to those of cancellous bone, QuickPack produces a calcium-deficient apatite that has similar composition and structure to natural bone mineral. The product is supplied in a user-friendly, self-contained, closed loop double-syringe delivery system, eliminating the need for open air mixing in a bowl and messy/inadequate transfer of material for injection. Responding directly to a medical need and to surgeons’ request, this unique solution complements the surgeon's tools box when performing bone reconstructive and trauma surgery by temporarily filling the defect and allowing new bone to form during the healing process.
Through a new partnership with Graftys®, an innovation-driven, research-based medical technology company committed to the development and manufacturing of synthetic bone biomaterials, OrthoPediatrics will offer QuickPack, through a private label agreement within the U.S.
Joe Hauser, OrthoPediatrics’ Vice President of Trauma & Deformity Correction, commented, “With the domestic launch of QuickPack, we further our mission to surround our surgeon customers with all modalities to treat their patients. The addition of this innovative bone void filler cement to our product offering is another demonstration of our ability to acquire and enhance proven technologies. We look forward to expanding our hospital and customer base through this new partnership.”
About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 33 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 43 countries outside the United States.
The Ruth Group
Tram Bui / Emma Poalillo
(646) 536-7035 / 7024
email@example.com / firstname.lastname@example.org
|2850 Frontier Drive|
Warsaw, Indiana 46582
|TRAUMA & DEFORMITY||SPINE||SPORTS MEDICINE||CLINICAL EDUCATION|